Prospects for phosphoinositide 3-kinase inhibition as a cancer treatment

Endocrine-Related Cancer

Volumn 8, Issue 3, 2001, Pages 237-248

  Stein, R C ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; DEMETHOXYVIRIDIN; ISOENZYME; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN KINASE; QUERCETIN; TEMSIROLIMUS; UNCLASSIFIED DRUG; WORTMANNIN;

CANCER; CANCER CHEMOTHERAPY; CARBOHYDRATE METABOLISM; CARCINOGENESIS; CELL MOTILITY; CELL PROLIFERATION; CELL SURVIVAL; CONFERENCE PAPER; DRUG SELECTIVITY; DRUG TARGETING; ENZYME ACTIVATION; ENZYME ACTIVE SITE; NONHUMAN; PROTEIN FAMILY; REGULATORY MECHANISM; SIGNAL TRANSDUCTION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; ANTINEOPLASTIC AGENTS; ENZYME INHIBITORS; HUMANS; LIPID METABOLISM; NEOPLASMS;

EID: 0034794639     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/erc.0.0080237     Document Type: Conference Paper

References (64)

1. Mutational spectra of PTEN/MMAC1 gene: A tumor suppressor with lipid phosphatase activity
2. The catalytic subunit of phosphoinositide 3-kinase: Requirements for oncogenicity
3. A role of the kinase mTOR in cellular transformation induced by the oncoproteins P3k and Akt
4. Class II phosphoinositide 3-kinases are downstream targets of activated polypeptide growth factor receptors
5. Enhanced phosphorylation of p53 by ATM in response to DNA damage
6. Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas
7. Proliferative defect and embryonic lethality in mice homozygous for a deletion in the p110alpha subunit of phosphoinositide 3-kinase
8. Increased phosphoinositide 3-kinase activity induces a lymphoproliferative disorder and contributes to tumor generation in vivo
9. Direct inhibition of the signaling functions of the mammalian target of rapamycin by the phosphoinositide 3-kinase inhibitors, wortmannin and LY294002
10. Phosphatidyl3-OH-kinases are Rab5 effectors
11. Overexpression of a kinase-inactive ATR protein causes sensitivity to DNA-damaging agents and defects in cell cycle checkpoints
12. Cell biology. Moving in mysterious ways
13. Specificity and mechanism of action of some commonly used protein kinase inhibitors
14. Target of rapamycin (TOR): Balancing the opposing forces of protein synthesis and degradation
15. The multiple roles of PTEN in tumor suppression
16. Phosphoinositide kinases
17. Hypoglycaemia, liver necrosis and perinatal death in mice lacking all isoforms of phosphoinositide 3-kinase p85 alpha
18. The rapamycin-sensitive signal transduction pathway as a target for cancer therapy
19. The PI 3-kinase isoforms p110(alpha) and p110(beta) have differential roles in PDGF- and insulin-mediated signaling
20. 3-(Hydroxymethyl)-bearing phosphatidylinositol ether lipid analogues and carbonate surrogates block PI3-K, Akt, and cancer cell growth
21. p85Alpha gene generates three isoforms of regulatory subunit for phosphatidylinositol 3-kinase (PI 3-kinase), p50alpha, p55alpha, and p85alpha, with different PI 3-kinase activity elevating responses to insulin
22. Five isoforms of the phosphatidylinositol 3-kinase regulatory subunit exhibit different associations with receptor tyrosine kinases and their tyrosine phosphorylations
23. Competitive and noncompetitive inhibition of the DNA-dependent protein kinase
24. Identification and characterization of a new oncogene derived from the regulatory subunit of phosphoinositide 3-kinase
25. PDGF induces an early and a late wave of PI 3-kinase activity, and only the late wave is required for progression through G1
26. Suppression of c-Myc-induced apoptosis by Ras signalling through PI(3)K and PKB
27. Matrix adhesion and Ras transformation both activate a phosphoinositide 3-OH kinase and protein kinase B/Akt cellular survival pathway
28. Activation of phosphatidylinositol 3-kinase is sufficient for cell cycle entry and promotes cellular changes characteristic of oncogenic transformation
29. Perspectives: Cell biology. All creatures great and small
30. PIK3CA as an oncogene in cervical cancer
31. A family of phosphoinositide 3-kinases in Drosophila identifies a new mediator of signal transduction
32. Up-regulation of Akt3 in estrogen receptor-deficient breast cancers and androgen-independent prostate cancer lines
33. Studies on the mechanism of phosphatidylinositol 3-kinase inhibition by wortmannin and related analogs
34. Crystal structure and functional analysis of Ras binding to its effector phosphoinositide 3-kinase gamma
35. Increased levels of phosphatidylinositol 3-kinase activity in colorectal tumors
36. Wortmannin, a potent and selective inhibitor of phosphatidylinositol-3-kinase
37. The phosphatidylinositol 3-kinase alpha is required for DNA synthesis induced by some, but not all, growth factors
38. A function for phosphatidylinositol 3-kinase beta (p85alpha-p110beta) in fibroblasts during mitogenesis: Requirement for insulin- and lysophosphatidic acid-mediated signal transduction
39. A novel positive feedback loop mediated by the docking protein Gab1 and phosphatidylinositol 3-kinase in epidermal growth factor receptor signaling
40. ATM: A mediator of multiple responses to genotoxic stress
41. Colorectal carcinomas in mice lacking the catalytic subunit of PI(3)Kgamma
42. PIK3CA is implicated as an oncogene in ovarian cancer
43. Phosphoinositide 3-kinase: The key switch mechanism in insulin signalling
44. The conserved phosphoinositide 3-kinase pathway determines heart size in mice
45. Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway
46. The DNA-dependent protein kinase
47. Xid-like immunodeficiency in mice with disruption of the p85alpha subunit of phosphoinositide 3-kinase
48. Increased insulin sensitivity and hypoglycaemia in mice lacking the p85 alpha subunit of phosphoinositide 3-kinase
49. Phospholipase C-gamma 1 and phosphatidylinositol 3 kinase are the downstream mediators of the PDGF receptor's mitogenic signal
50. Signaling by distinct classes of phosphoinositide 3-kinases
51. The PI3K-PDK1 connection: More than just a road to PKB
52. The study of phosphoinositide 3-kinase function
53. Distinct PI(3)Ks mediate mitogenic signalling and cell migration in macrophages
54. Synthesis and function of 3-phosphorylated inositol lipids
55. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002)
56. Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine
57. Actin filaments participate in the relocalization of phosphatidylinositol3-kinase to glucose transporter-containing compartments and in the stimulation of glucose uptake in 3T3-L1 adipocytes
58. Expression, enzyme activity, and subcellular localization of mammalian target of rapamycin in insulin-responsive cells
59. A comparison of demethoxyviridin and wortmannin as inhibitors of phosphatidylinositol 3-kinase
60. Structure and function of phosphoinositide 3-kinases
61. Wortmannin inactivates phosphoinositide 3-kinase by covalent modification of Lys-802, a residue involved in the phosphate transfer reaction
62. 3Beta-hydroxy-6-aza-cholestane and related analogues as phosphatidylinositol specific phospholipase C (PI-PLC) inhibitors with antitumor activity
63. Requirement for phosphatidylinositol-3 kinase in the prevention of apoptosis by nerve growth factor
64. Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase/Akt pathway in human ovarian cancer